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access provincial data is underway. The RISC continues to work 
through the NSIR-RT pilot to mitigate the identified barriers in 
an effort to improve provincially provided care. 
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Purpose: Pathological response to neoadjuvant therapy has been 
linked to long-term outcome in rectal cancer (RC). Predicting 
nodal response is important especially in cases where watch and 
wait strategy is being considered. This study was carried out to 
identify potential predictors of pathological nodal response after 
long course chemoradiotherapy (CRT). 
Methods and Materials: A retrospective review of all patients 
with clinically node positive RC who received neoadjuvant CRT 
in Manitoba between January 2007 and December 2012 was 
conducted. Pre CRT tumour staging, treatment-related 
hematologic toxicities and pathologic nodal response data were 
recorded. Univariable and Multivariable analyses were 
performed using Bayesian logistic regression models. 
Results: Two hundred and six patients with clinically node 
positive RC were included in this study. The mean number of 
excised nodes was 16.35. One hundred and seventeen patients 
(56.8%) achieved a pathologic complete nodal response. Higher 
pre-treatment carcinoembryonic antigen (CEA) level (p = 0.0072) 
and presence of lymphovascular space invasion (LVI) in the 
surgical specimen (p = 0.0002) were independent predictors of 
lack of nodal response. In the univariable analysis, there was a 
tendency to a better response in patients who developed less 
treatment-induced lymphocytopenia. 
Conclusions: Pre-treatment CEA and presence of LVI predicted 
less pathological nodal response post CRT for rectal cancer. LVI 
is a pathological finding, however, signs of vascular invasion can 
be detected on the pre-treatment MRI. These results could 
potentially be used to identify favourable responders to CRT and 
guide management strategies of rectal cancer especially when 
organ and function preservation are pursued. 
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Purpose:  Stereotactic body radiotherapy (SBRT) can treat 
hepatocellular (HCC) patients who are not eligible for surgery, 
trans-arterial chemoembolization or radiofrequency ablation. 
This study aims to compare the efficacy and toxicity of SBRT to 
small tumours (< 4.4 cm, our median population size) and 
moderate to large tumours (≥ 4.4 cm). 
Methods and Materials: A retrospective study of the first 48 
provincially treated HCC patients (March 2011-July 2015) was 
conducted. All patients were discussed at multidisciplinary 
rounds and considered ineligible for further standard local 
therapies. Local control (LC), progression free survival (PFS), 
overall survival (OS) and toxicities were analyzed. 
Results: Fifty-one separate hepatomas were treated with a 
median size of 4.4cm (range: 1.3-15.6cm). Baseline 
demographics, performance status, previous liver-directed 
treatments, and Child’s Pugh (CP) score were similar between 
the groups. Hepatitis B was more common in the ≥4.4cm group 
while Hepatitis C was more common in the < 4.4 cm group (p = 
0.05). RT doses were 36 to 50 Gy in three to 10 fractions, with 
87% of patients receiving 45 Gy in 3 or 5 fractions. Twenty-eight 
(55%) hepatomas were treated with a biological equivalent dose 
(BED10) ≥ 100 Gy and 45 (88.3%) were treated with a BED10 ≥ 80 
Gy. Tumours <4.4cm were more likely to be treated with a BED10 
≥ 80 Gy (p < 0.001). Seven patients (15%) had worsened CP score 
by > 1 point at three months post-SBRT, but this was not different 
between the two groups (p = 0.86). LC for all patients was 94% 
at one and two years, and was comparable for tumours < 4.4 cm 
and ≥ 4.4 cm (two year LC: 96% for < 4.4 cm versus 92% for ≥ 4.4 
cm, p = 0.91). OS for all patients was 65% at two years (87% for 
< 4.4 cm versus 46% for ≥ 4.4 cm, p = 0.07). PFS was 38% at two 
years for all patients, and did not differ significantly between 
groups (p = 0.70). On univariate analysis, BED10 ≥ 80 Gy was the 
only factor associated with improved PFS, while both BED10 ≥ 80 
Gy and normal baseline AFP were associated with improved OS. 
Conclusions: SBRT provides high local control for patients with 
inoperable HCC and can be delivered with acceptable risk for 
post-treatment hepatic injury even for moderate to large sized 
tumours. Radiation doses above BED10 of 80 Gy improved PFS 
and OS in our cohort. 
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Purpose: Concurrent chemoradiation (CRT) with fluorouracil (5-
FU) and mitomycin C (MMC) is standard treatment for anal canal 
carcinoma (ACC). However, treatment varies based on available 
RT technology and centre preference for chemotherapy (CT) 
regimen. The purpose of this study was to compare dosimetric 
parameters, toxicity, and outcomes in ACC patients treated with 
two different RT modalities and CT regimens. 
Methods and Materials: This is a retrospective study of 
consecutive ACC patients treated with radical CRT at two 
tertiary cancer centres from 2008-2012. Patients were grouped 
according to RT modality (IMRT versus HT), and CT regimen (5-
FU with: one cycle MMC, MMC1 versus two cycles, MMC2). 
Primary endpoints were dosimetric comparison between the RT 
cohorts and toxicity comparison between the CT cohorts; 
secondary endpoint was comparison of outcomes, including 
patterns of failure, disease-free survival (DFS), overall survival 
(OS), colostomy-free survival (CFS). 
Results: Of 64 patients in total, 34 (53%) were treated with IMRT 
and 30 (47%) with HT. Patient and tumour characteristics were 
not significantly different between the groups. Twenty-six 
patients (43%) received MMC1, while 34 (57%) patients received 
MMC2; 4 patients received 5FU/cisplatin. The majority (25/34, 
74%) of IMRT patients received MMC1, while most HT patients 
(29/30, 97%) received MMC2 (p < 0.01), which correlated with 
treatment centre. HT achieved more homogenous coverage of 
the primary tumour (HT homogeneity and uniformity index 0.15 
and 1.03 versus 0.29 and 1.06 for IMRT, p < 0.01 and p < 0.01). 
IMRT achieved better bladder, femoral head and peritoneal 
space sparing, and lower skin dose (p < 0.01 for all). HT achieved 
lower bone marrow and external genitalia dose (both p < 0.01) 
versus IMRT. Comparing CT regimens, MMC2 was more strongly 
associated with Grade 2+ neutropenia (p = 0.03) and Grade 4 
toxicity (p = 0.03) versus MMC1. There were no differences in 
local, regional or distant failure based on RT modality (p = 0.46, 
p = 0.62, p = 0.12, respectively) or CT regimen (p = 1.0, p = 0.31, 
p = 0.16). Additionally, there were no differences in OS, DFS or 
